Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Polycystic Ovary Syndrome 2Neoplasms 2Diabetes Mellitus, Type 2 2Thyroid Cancer, Papillary 1Solid Cancers 1Sezary Syndrome 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Obesity 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Liposarcoma 1Leukoplakia, Oral 1Carcinoma, Renal Cell 1Breast Neoplasms 1Alzheimer Disease 1Adenocarcinoma, Follicular 1

Interventions

Photochemotherapy 2Biopsy 2Tobacco Products 1Sulindac 1Rosiglitazone 1Pioglitazone 1Nivolumab 1Gene Expression Profiling 1Fluconazole 1Ethanol 1Dihematoporphyrin Ether 1Dapsone 1Celecoxib 1Catechin 1Behavior Therapy 1Aspirin 1Acyclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukoplakia, Oral × Rosiglitazone × Clear all
NCT00369174 2013-02-13

Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

National Cancer Institute (NCI)

Phase 2 Completed
25 enrolled
Head & Neck

Leukoplakia, Oral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡